Amarantus BioScience Holdings, Inc.   Report issue

For profit Phase 2
Founded: New York NY United States (2008)
Status: Acquired by Avant Immunotherapeutics (2016) → now Celldex Therapeutics (2008)

Organization Overview

First Clinical Trial
2011
NCT01266174
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree